The health economic impact of varying levels of adherence to colorectal screening on providers and payers

References

• National Cancer Institute. Cancer stat facts: colorectal cancer. 2020. [cited 2020 Apr 10]. Available from: https://seer.cancer.gov/statfacts/html/colorect.html
   Google Scholar
• Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA. 2016;315(23):2564–2575.
   PubMed Web of Science ®Google Scholar
• Frazier AL, Colditz GA, Fuchs CS, et al. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 2000;284(15):1954–1961.
   PubMed Web of Science ®Google Scholar
• Goede SL, Kuntz KM, van Ballegooijen M, et al. Cost-savings to Medicare from pre-medicare colorectal cancer screening. Med Care. 2015;53(7):630–638.
   PubMed Web of Science ®Google Scholar
• Knudsen AB, Zauber AG, Rutter CM, et al. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US preventive services task force. JAMA. 2016;315(23):2595–2609.
   PubMed Web of Science ®Google Scholar
• Subramanian S, Bobashev G, Morris RJ. Modeling the cost-effectiveness of colorectal cancer screening: policy guidance based on patient preferences and compliance. Cancer Epidemiol Biomarkers Prev. 2009;18(7):1971–1978.
   PubMed Web of Science ®Google Scholar
• Vijan S, Hwang EW, Hofer TP, et al. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med. 2001;111(8):593–601.
   PubMed Web of Science ®Google Scholar
• Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250–281.
   PubMed Web of Science ®Google Scholar
• Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008;103(6):1541–1549.
   PubMed Web of Science ®Google Scholar
• Doubeni CA, Corley DA, Quinn VP, et al. Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study. Gut. 2018;67(2):291–298.
   PubMed Web of Science ®Google Scholar
• Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369(12):1095–1105.
   PubMed Web of Science ®Google Scholar
• Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012;366(25):2345–2357.
   PubMed Web of Science ®Google Scholar
• Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial-SCORE. J Natl Cancer Inst. 2011;103(17):1310–1322.
   PubMedGoogle Scholar
• Atkin W, Wooldrage K, Parkin DM, et al. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial. Lancet. 2017;389(10076):1299–1311.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Colorectal cancer facts & figures 2020–2022. [cited 2020 Apr 24]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2020-2022.pdf
   Google Scholar
• Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. JAMA Int Med. 2012;172(7):575–582.
   Google Scholar
• Liang PS, Wheat CL, Abhat A, et al. Adherence to competing strategies for colorectal cancer screening over 3 years. Am J Gastroenterol. 2016;111(1):105–114.
   PubMed Web of Science ®Google Scholar
• Zauber A, Knudsen AB, Rutter CM, et al. Evaluating the benefits and harms of colorectal cancer screening strategies: a collaborative modeling approach. Rockville (MD): Agency for Healthcare Research and Quality; 2015.
   Google Scholar
• Kuntz KM, Lansdorp-Vogelaar I, Rutter CM, et al. A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Making. 2011;31(4):530–539.
   PubMed Web of Science ®Google Scholar
• Arrospide A, Idigoras I, Mar J, et al. Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model. BMC Cancer. 2018;18(1):464.
   PubMed Web of Science ®Google Scholar
• Mannucci A, Zuppardo RA, Rosati R, et al. Colorectal cancer screening from 45 years of age: thesis, antithesis and synthesis. World J Gastroenterol. 2019;25(21):2565–2580.
   PubMed Web of Science ®Google Scholar
• Hathway JM, Miller-Wilson LA, Jensen IS, et al. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives. J Med Econ. 2020;23(6):581–592.
   PubMed Web of Science ®Google Scholar
• Chyhaniuk A, Coombes ME. Longitudinal adherence to colorectal cancer screening guidelines. Am J Manag Care. 2016;22(2):105–111.
   PubMed Web of Science ®Google Scholar
• van Roon AHC, Goede SL, van Ballegooijen M, et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut. 2013;62(3):409–415.
   PubMed Web of Science ®Google Scholar
• Manufacturer data on file. Cologuard's compliance rate represents the cumulative completed tests from kits shipped to patients during the six-month period ending 12 months prior to the end of the 2019, excluding program orders. 2019.
   Google Scholar
• Jensen CD, Corley DA, Quinn VP, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study fecal immunochemical test performance characteristics. Ann Intern Med. 2016;164(7):456–463.
   PubMed Web of Science ®Google Scholar
• Weiser E, Parks PD ,Swartz RK, et al. Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening: Real-world data from a large cohort of older adults. J Med Screen. 2020. DOI:https://doi.org/10.1177/0969141320903756
   Google Scholar
• Parente F, Boemo C, Ardizzoia A, et al. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy. Endoscopy. 2013;45(1):27–34.
   PubMed Web of Science ®Google Scholar
• Issaka RB, Singh MH ,Oshima SM, et al. Inadequate utilization of diagnostic colonoscopy following abnormal FIT results in an integrated safety-net system. Am J Gastroenterol. 2017;112(2):375–382.
   PubMed Web of Science ®Google Scholar
• Rutter CM, Yu O, Miglioretti DL. A hierarchical non-homogenous Poisson model for meta-analysis of adenoma counts. Stat Med. 2007;26(1):98–109.
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics. GMWK310, deaths by single years of age, race, and sex: United States, 1999–2007 [cited 2019 March]. Available from: https://www.cdc.gov/nchs/nvss/mortality/gmwk310.htm
   Google Scholar
• Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule. 2019. [cited 2019 Jun 1]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Clinical-Laboratory-Fee-Schedule-Files.html
   Google Scholar
• Imperiale TFR, Itzkowitz DF, H S. Multitarget stool DNA testing for colorectal-cancer screening. New Eng J Med. 2014;371(2):184–188.
   Google Scholar
• Administration, U.S.F.D. FDA summary of safety and effectiveness data. 2018.
   Google Scholar
• Pyenson B, Scammell C, Broulette J. Costs and repeat rates associated with colonoscopy observed in medical claims for commercial and Medicare populations. BMC Health Serv Res. 2014;14:92.
   Google Scholar
• Zauber AG, et al. AHRQ technology assessments. Cost-effectiveness of DNA stool testing to screen for colorectal cancer. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007.
   Google Scholar
• Subramanian S, Tangka FKL, Hoover S, et al. Costs of colorectal cancer screening provision in CDC’s Colorectal Cancer Control Program: comparisons of colonoscopy and FOBT/FIT based screening. Eval Program Plann. 2017;62:73–80.
   PubMed Web of Science ®Google Scholar
• Healthcare Cost and Utilization Project (HCUP). HCUP CCS - services and procedures. 2018. [2018 Dec 1]. Available from: https://hcupnet.ahrq.gov/#setup
   Google Scholar
• Medicare Payment Advisory Commission (MedPAC). Report to the congress: medicare payment policy. 2015. [cited 2019 Jul 30]. Available from: http://www.medpac.gov/docs/default-source/reports/mar2015_entirereport_revised.pdf
   Google Scholar
• Henry J Kaiser Family Foundation. Medicaid-to-Medicare fee index. 2016. [2019 Mar 1]. Available from: https://www.kff.org/medicaid/state-indicator/medicaid-to-medicare-fee-index/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D
   Google Scholar
• Sheridan SL, Harris RP, Woolf SH, et al. Shared decision making about screening and chemoprevention. a suggested approach from the U.S. Preventive Services Task Force. Am J Prev Med. 2004;26(1):56–66.
   PubMed Web of Science ®Google Scholar
• Volk RJ, Linder SK, Lopez-Olivo MA, et al. Patient decision aids for colorectal cancer screening: a systematic review and meta-analysis. Am J Prev Med. 2016;51(5):779–791.
   PubMed Web of Science ®Google Scholar
• Jones RM, Devers KJ, Kuzel AJ, et al. Patient-reported barriers to colorectal cancer screening: a mixed-methods analysis. Am J Prev Med. 2010;38(5):508–516.
   PubMed Web of Science ®Google Scholar